Diagnosis, Treatment and Prognosis of Pulmonary Fibrosis

Dear Colleagues,

Pulmonary fibrosis is a debilitating interstitial lung disease characterized by the excessive accumulation of fibrous tissue in the lungs. It can develop due to various identifiable triggers, including infections, silicosis, and connective tissue diseases. Moreover, a significant proportion of patients suffer from idiopathic pulmonary fibrosis (IPF), where the underlying cause remains unknown. An abundance of evidence underscores the critical importance of early diagnosis in ensuring timely treatment selection and improving the prognosis of pulmonary fibrosis. Regrettably, there is currently no established biomarker or “gold standard” for early pulmonary fibrosis diagnosis, contributing to treatment delays. Consequently, this special issue is dedicated to comprehensively exploring the multifaceted dimensions of pulmonary fibrosis, with a specific emphasis on early diagnosis, intervention, and its profound impact on patient prognosis.

We invite contributions spanning a wide range of topics, including but not limited to:

Early Diagnosis Strategies: Investigating and deliberating on the latest advancements in diagnostic tools and methodologies for the early detection of pulmonary fibrosis.

Therapeutic Approaches: Evaluating the effectiveness of current and emerging treatment modalities, with a primary focus on interventions capable of halting or reversing the disease's progression.

Prognostic Factors: Exploring the factors that influence patient prognosis, encompassing disease severity, genetic markers, and comorbidities.

Interdisciplinary Collaborations: Underlining the significance of collaboration between artificial intelligence (AI) and medicine in achieving early diagnosis and improving patient prognosis.

This Special Issue is designed to facilitate a deeper comprehension of pulmonary fibrosis, with an emphasis on the pivotal role of early diagnosis in enhancing patient prognosis. By providing a platform for the exchange of diverse perspectives and research findings, we aspire to instill renewed hope in patients and their families, ultimately contributing to improved outcomes in the battle against this devastating disease.

Dr. Yi Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pulmonary fibrosis
• interstitial lung disease
• early diagnosis strategies
• therapeutic approaches
• artificial intelligence
• biomarkers for prognostic assessment